Immune checkpoint blockade therapy has shown limited efficacy in head and neck squamous cell carcinoma (HNSCC).
Sialic acid binding immunoglobulin-like lectin (Siglec)-15 has been identified as a novel immune evasion biomarker, while the role of Siglec-10 in the specific immune suppressive tumor microenvironment remains largely unknown.
